Alcohol Dependence & Withdrawal
Summary
Alcohol dependence (alcohol use disorder, AUD) is a chronic relapsing condition characterised by compulsive alcohol use, loss of control over intake, and a negative emotional state when not drinking. Alcohol withdrawal syndrome (AWS) occurs when chronic heavy drinkers suddenly reduce or stop drinking, ranging from mild tremor and anxiety to life-threatening delirium tremens and seizures. Management of AWS requires careful assessment, thiamine replacement, and benzodiazepine-based detoxification. Long-term recovery requires pharmacotherapy, psychological support, and engagement with mutual aid groups.
Key Facts
- Prevalence: 5-10% of adults meet criteria for AUD; 20% of hospital inpatients
- Mortality: Delirium tremens has 5-15% mortality if untreated
- Wernicke's encephalopathy: Caused by thiamine (B1) deficiency; preventable with IV thiamine
- Withdrawal timeline: Tremor 6-12h → Seizures 12-48h → DTs 48-72h
- Key management: Thiamine BEFORE glucose; symptom-triggered benzodiazepines
- Prevention of relapse: Acamprosate, naltrexone, disulfiram, psychosocial support
Clinical Pearls
Thiamine Before Glucose: Always give IV thiamine before any glucose-containing fluids in at-risk patients. Glucose administration can precipitate or worsen Wernicke's encephalopathy.
The 48-72 Hour Window: Delirium tremens typically develops 48-72 hours after the last drink. Patients who appear stable at 24 hours may still deteriorate — maintain vigilance.
The Concealed Drinker: Hospital inpatients often underreport alcohol use. Any patient with unexplained tremor, confusion, or agitation 2-3 days into admission should be assessed for AWS.
Why This Matters Clinically
Alcohol withdrawal is common in hospital settings and frequently unrecognised until complications occur. Delirium tremens carries significant mortality and morbidity. Early recognition and treatment prevent seizures, aspiration, and death. Wernicke's encephalopathy is preventable but irreversible once Korsakoff's syndrome develops.
Incidence & Prevalence
- AUD prevalence: 5-10% of adults in UK
- Hospital inpatients: 20% drink at hazardous levels
- AWS incidence: 50% of alcohol-dependent patients experience withdrawal
- DT incidence: 3-5% of those with withdrawal
- Wernicke's encephalopathy: 0.4-2.8% of dependent drinkers; often underdiagnosed
Demographics
| Factor | Details |
|---|---|
| Age | Peak 18-29 years; chronic dependence in older adults |
| Sex | Male 2x more likely; women progress faster |
| Socioeconomic | All groups affected; higher rates in deprivation |
| Psychiatric comorbidity | 50% have concurrent mental health disorder |
Risk Factors for Severe Withdrawal
Predicting Severe AWS/DT:
- Previous DT or withdrawal seizures
- Prolonged heavy drinking (greater than 8 units/day)
- Previous complicated withdrawal
- Concurrent medical illness
- Age greater than 40
| Risk Factor | Impact |
|---|---|
| Previous DT | 5x risk of recurrence |
| Previous seizures | 3x risk |
| High alcohol intake | Dose-dependent |
| Concurrent illness | Increases severity |
Mechanism
Step 1: Chronic Alcohol Exposure
- Alcohol enhances inhibitory GABA-A receptor activity
- Alcohol inhibits excitatory NMDA glutamate receptors
- Brain adapts: downregulation of GABA receptors, upregulation of NMDA receptors
Step 2: Withdrawal State
- Sudden cessation removes inhibitory effect
- Relative excess of excitatory glutamatergic activity
- Sympathetic nervous system activation
- Neuronal hyperexcitability
Step 3: Clinical Manifestations
- Mild: Tremor, anxiety, insomnia (6-12 hours)
- Moderate: Hallucinations, hypertension, tachycardia (12-24 hours)
- Severe: Seizures, delirium tremens (24-72 hours)
Step 4: Wernicke's Encephalopathy (Separate Pathway)
- Thiamine (B1) deficiency from malnutrition and malabsorption
- Impaired glucose metabolism in vulnerable brain regions
- Damage to mammillary bodies, medial thalamus, brainstem
- Triad: Confusion, ataxia, ophthalmoplegia
Classification
Alcohol Use Disorder (DSM-5):
- Mild: 2-3 criteria
- Moderate: 4-5 criteria
- Severe: 6+ criteria
Withdrawal Severity:
| Stage | Timeline | Features |
|---|---|---|
| Mild | 6-12 hours | Tremor, anxiety, insomnia, nausea, sweating |
| Moderate | 12-24 hours | Tachycardia, hypertension, fever, hallucinations |
| Severe DT | 48-72 hours | Delirium, seizures, autonomic instability |
Symptoms
Alcohol Dependence:
Withdrawal Syndrome:
Delirium Tremens:
Wernicke's Encephalopathy Triad:
Signs
Red Flags
[!CAUTION] Red Flags — Urgent treatment required if:
- Seizures (may be first presentation)
- Delirium (confusion, hallucinations, agitation) — DT
- Confusion + ataxia ± ophthalmoplegia — Wernicke's encephalopathy
- Hyperthermia (temperature greater than 38.5°C)
- Cardiovascular instability (severe hypertension or hypotension)
Structured Approach
General:
- Vital signs (HR, BP, temperature, RR)
- Level of consciousness and orientation
- Hydration status
- Signs of chronic liver disease (jaundice, spider naevi, hepatomegaly)
Neurological:
- Tremor assessment
- Eye movements (nystagmus, ophthalmoplegia)
- Gait (ataxia)
- Reflexes (hyperreflexia in withdrawal)
- Confusion/orientation (AMT, 4AT)
Cardiovascular:
- Heart rate and rhythm
- Blood pressure
Special Tests
| Test | Technique | Positive Finding | Purpose |
|---|---|---|---|
| CIWA-Ar | Standardised assessment tool | Score greater than 10 indicates need for treatment | Guide benzodiazepine dosing |
| CAGE Questionnaire | 4 questions | 2+ positive = likely dependence | Screening |
| AUDIT | 10-item questionnaire | Score greater than 8 = hazardous drinking | Comprehensive screening |
| SADQ | 20-item questionnaire | Score indicates severity | Assess dependence severity |
First-Line (Bedside)
- Observations — HR, BP, temperature, RR
- Blood glucose — Hypoglycaemia common
- CIWA-Ar score — Guides treatment
- Urinalysis — Exclude UTI as cause of confusion
Laboratory Tests
| Test | Expected Finding | Purpose |
|---|---|---|
| FBC | Macrocytosis (MCV greater than 100), anaemia | Chronic alcohol effect |
| LFTs | Raised GGT, AST:ALT greater than 2:1 | Liver damage |
| U&Es | Hypokalaemia, hypomagnesaemia, hyponatraemia | Electrolyte disturbance |
| Clotting | Prolonged PT/INR if liver failure | Liver synthetic function |
| Glucose | May be low | Malnutrition, impaired gluconeogenesis |
| Amylase/Lipase | Elevated if pancreatitis | Complication screening |
| Blood alcohol level | May still be elevated or zero | Contextual information |
Imaging
| Modality | Findings | Indication |
|---|---|---|
| CT Head | Exclude subdural haematoma, infarct | If focal neurology, fall, confusion |
| CXR | Aspiration pneumonia | If respiratory symptoms |
| MRI Brain | Mammillary body changes (Wernicke's) | If Wernicke's suspected and diagnostic uncertainty |
Management Algorithm
ALCOHOL WITHDRAWAL SYNDROME
↓
┌─────────────────────────────────────────┐
│ ASSESS SEVERITY (CIWA-Ar) │
│ Vitals, orientation, tremor, sweating │
└─────────────────────────────────────────┘
↓
┌─────────────────────────────────────────┐
│ THIAMINE (PABRINEX) │
│ IV Pabrinex BEFORE any glucose │
│ 1 pair TDS for 3-5 days (prophylaxis) │
│ 2 pairs TDS if Wernicke's suspected │
└─────────────────────────────────────────┘
↓
┌─────────────────────────────────────────┐
│ BENZODIAZEPINE REGIMEN │
├─────────────────────────────────────────┤
│ CIWA-Ar <10: Monitor │
│ CIWA-Ar 10-15: Chlordiazepoxide PRN │
│ CIWA-Ar >15: Symptom-triggered dosing │
│ SEVERE DT: IV Diazepam or Lorazepam │
└─────────────────────────────────────────┘
↓
┌─────────────────────────────────────────┐
│ CORRECT ELECTROLYTES │
│ K⁺, Mg²⁺, PO₄³⁻ as needed │
└─────────────────────────────────────────┘
↓
┌─────────────────────────────────────────┐
│ RELAPSE PREVENTION │
│ Acamprosate, Naltrexone, Disulfiram │
│ Psychological support, AA referral │
└─────────────────────────────────────────┘
Acute/Emergency Management
Immediate Actions:
- Secure airway if reduced consciousness
- IV access, bloods including glucose
- IV Pabrinex (thiamine) — BEFORE glucose
- Benzodiazepines for withdrawal symptoms
- Correct electrolyte abnormalities
- Monitor with CIWA-Ar scoring
IV Thiamine Dosing:
- Prophylaxis: Pabrinex 1 pair (1 x 10ml ampoule pair) TDS for 3-5 days
- Wernicke's encephalopathy: Pabrinex 2 pairs TDS for minimum 5 days, then oral
Conservative Management
- Quiet, well-lit room to minimise hallucinations
- Reassurance and orientation
- Hydration (oral preferred if tolerated)
- Nutritional support
Medical Management
Benzodiazepines (Core Treatment):
| Drug | Indication | Regimen |
|---|---|---|
| Chlordiazepoxide | First-line (oral) | Reducing regimen: 30mg QDS → reduce by 20% daily over 5-7 days |
| Diazepam | Alternative oral or IV | 10-20mg PRN or reducing regimen |
| Lorazepam | Liver failure (shorter acting) | 1-2mg IM/IV PRN |
Symptom-Triggered Therapy:
- Give chlordiazepoxide 10-20mg PRN when CIWA-Ar greater than 10
- Reassess hourly
- Reduces total benzodiazepine dose and treatment duration
Relapse Prevention:
| Drug | Mechanism | Dose | Notes |
|---|---|---|---|
| Acamprosate | GABA modulation, reduces craving | 666mg TDS | First-line; not hepatotoxic |
| Naltrexone | Opioid antagonist, reduces reward | 50mg OD | Contraindicated if active hepatitis |
| Disulfiram | Aldehyde dehydrogenase inhibitor | 200mg OD | Causes severe reaction with alcohol; requires motivation |
Surgical Management
- Not applicable
Disposition
- Admit if: Moderate-severe withdrawal (CIWA greater than 15), history of DT/seizures, comorbid illness, unable to self-care
- Discharge if: Mild withdrawal, stable community support, planned outpatient detox, motivated patient
- Follow-up: Alcohol liaison service, community addiction services, GP for ongoing prescribing
Immediate
| Complication | Incidence | Presentation | Management |
|---|---|---|---|
| Seizures | 3-7% of withdrawal | Generalised tonic-clonic | Lorazepam 4mg IV, increase benzodiazepines |
| Delirium tremens | 3-5% | Confusion, hallucinations, autonomic instability | High-dose benzodiazepines, ICU if severe |
| Wernicke's encephalopathy | 0.4-2.8% | Confusion, ataxia, ophthalmoplegia | IV Pabrinex |
Early (Days)
- Aspiration pneumonia: From reduced consciousness, vomiting
- Electrolyte disturbance: Hypokalaemia, hypomagnesaemia cause arrhythmias
- Hypoglycaemia: Malnutrition, impaired gluconeogenesis
Late (Weeks-Months)
- Korsakoff's syndrome: Irreversible amnestic syndrome (anterograde and retrograde amnesia, confabulation) — follows untreated Wernicke's
- Relapse: 40-60% within first year
- Chronic liver disease: Alcoholic hepatitis, cirrhosis
Natural History
- Mild withdrawal: Self-limiting over 3-5 days
- Severe withdrawal: Progresses to DT if untreated
- Untreated DT: 5-15% mortality
- Wernicke's: 17% mortality; 80% develop Korsakoff's if untreated
Outcomes with Treatment
| Variable | Outcome |
|---|---|
| Mortality with treatment | Less than 1% (DT) |
| Abstinence at 1 year (no pharmacotherapy) | 20-30% |
| Abstinence at 1 year (with pharmacotherapy) | 40-50% |
| Recovery from Wernicke's | 80% with prompt treatment |
Prognostic Factors
Good Prognosis:
- Motivation to change
- Strong social support
- Engagement with addiction services
- No previous complicated withdrawal
Poor Prognosis:
- Previous DT or seizures
- Multiple relapses
- Concurrent mental health disorder
- Homelessness or lack of social support
- Advanced liver disease
Key Guidelines
- NICE CG115 (2011) — Alcohol-use disorders: diagnosis and management. NICE CG115
- NICE CG100 — Alcohol-use disorders: prevention.
- SIGN 74 — The management of harmful drinking and alcohol dependence in primary care.
Landmark Trials
COMBINE Study (2006) — Combining medications and behavioural interventions
- 1383 patients randomised to naltrexone, acamprosate, behavioural intervention, combinations
- Key finding: Naltrexone and behavioural intervention both effective; no added benefit of combining all
- Clinical Impact: Supports pharmacotherapy plus psychosocial intervention
UKATT Trial (2005) — UK Alcohol Treatment Trial
- 742 patients randomised to motivational enhancement therapy vs social behaviour network therapy
- Key finding: Both equally effective; outcomes depend on engagement
- Clinical Impact: Emphasises importance of any structured intervention
Evidence Strength
| Intervention | Level | Key Evidence |
|---|---|---|
| Benzodiazepines for withdrawal | 1a | Cochrane review |
| Symptom-triggered therapy | 1b | RCTs show reduced duration and dose |
| Thiamine for Wernicke's prevention | 2a | Cohort studies, pathophysiological rationale |
| Acamprosate for relapse prevention | 1a | Cochrane review |
| Naltrexone for relapse prevention | 1a | COMBINE trial, Cochrane review |
What is Alcohol Dependence?
Alcohol dependence, also called alcoholism or alcohol use disorder, is when you find it very difficult to control your drinking even though it is causing problems in your life. Your body becomes used to alcohol, needing more to feel the same effect, and you feel unwell when you try to stop drinking.
What is Alcohol Withdrawal?
When someone who drinks heavily every day suddenly stops or cuts down, their body reacts. This is called withdrawal. Symptoms range from shaking, sweating, and feeling anxious to serious problems like fits (seizures) and confusion. The most severe form, called delirium tremens (DTs), can be life-threatening.
How is it treated?
- In hospital or at home: Depending on severity, you may need to be in hospital or can sometimes be treated at home with regular nurse visits.
- Vitamins: We give vitamin B1 (thiamine) through a drip to prevent brain damage.
- Medication for withdrawal: Tablets (usually chlordiazepoxide) help calm the brain and prevent fits. The dose is gradually reduced over 5-7 days.
- Preventing relapse: Medications like acamprosate or naltrexone reduce cravings. Counselling and support groups (like AA) help you stay alcohol-free.
What to expect
- Withdrawal symptoms usually peak at 24-72 hours and improve over 5-7 days
- You may feel tired, anxious, and have trouble sleeping for a few weeks
- Recovery is a long-term process — relapses are common but do not mean failure
- With the right support, many people achieve lasting recovery
When to seek help
Go to A&E or call 999 if you:
- Have a seizure (fit)
- Feel very confused or see/hear things that aren't there
- Have severe shaking that won't stop
- Feel your heart beating very fast or irregularly
- Have a high temperature with severe sweating
Primary Guidelines
- National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis and management of physical complications (CG100). 2010. NICE CG100
- National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence (CG115). 2011. NICE CG115
Key Trials
- Anton RF, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-17. PMID: 16670409
- UKATT Research Team. Effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ. 2005;331(7516):541. PMID: 16150764
- Amato L, et al. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev. 2010;(3):CD005063. PMID: 20238338
Further Resources
- Alcoholics Anonymous: alcoholics-anonymous.org.uk
- Drinkaware: drinkaware.co.uk
- NHS Alcohol Support: nhs.uk/live-well/alcohol-advice
Last Reviewed: 2025-12-24 | MedVellum Editorial Team
Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.